{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:35:57Z","timestamp":1792445757908,"version":"4.5.0"},"reference-count":184,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Berlin Institute of Health Biomedical Innovation Academy","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The ubiquitin\u2013proteasome system (UPS) is involved in multiple cellular functions including the regulation of protein homeostasis, major histocompatibility (MHC) class I antigen processing, cell cycle proliferation and signaling. In humans, proteasome loss-of-function mutations result in autoinflammation dominated by a prominent type I interferon (IFN) gene signature. These genomic alterations typically cause the development of proteasome-associated autoinflammatory syndromes (PRAAS) by impairing proteasome activity and perturbing protein homeostasis. However, an abnormal increased proteasomal activity can also be found in other human inflammatory diseases. In this review, we cast a light on the different clinical aspects of proteasomal activity in human disease and summarize the currently studied therapeutic approaches.<\/jats:p>","DOI":"10.3390\/jcm10081783","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T05:35:25Z","timestamp":1618896925000},"page":"1783","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Role of Proteasomes in Inflammation"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3407-7631","authenticated-orcid":false,"given":"Carl Christoph","family":"Goetzke","sequence":"first","affiliation":[{"name":"Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Department of Pediatrics, Division of Pulmonology, Immunology and Critical Care Medicine, Augustenburger Platz 1, 13353 Berlin, Germany"},{"name":"Berlin Institute of Health at Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Charit\u00e9platz 1, 10117 Berlin, Germany"},{"name":"Deutsches Rheumaforschungszentrum, Charit\u00e9platz 1, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3729-7878","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Ebstein","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsmedizin Greifswald, Institute of Medical Biochemistry and Molecular Biology, 7475 Greifswald, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilmann","family":"Kallinich","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Department of Pediatrics, Division of Pulmonology, Immunology and Critical Care Medicine, Augustenburger Platz 1, 13353 Berlin, Germany"},{"name":"Berlin Institute of Health at Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Charit\u00e9platz 1, 10117 Berlin, Germany"},{"name":"Deutsches Rheumaforschungszentrum, Charit\u00e9platz 1, 10117 Berlin, Germany"},{"name":"Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin, Center for Chronically Sick Children, Augustenburger Platz 1, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/sj.cdd.4401692","article-title":"Intracellular protein degradation: From a vague idea thru the lysosome and the ubiquitin\u2013proteasome system and onto human diseases and drug targeting","volume":"12","author":"Ciechanover","year":"2005","journal-title":"Cell Death Differ."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bbamcr.2013.06.031","article-title":"Protein quality control and elimination of protein waste: The role of the ubiquitin\u2013proteasome system","volume":"1843","author":"Amm","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.aax3769","article-title":"Cellular quality control by the ubiquitin-proteasome system and autophagy","volume":"366","author":"Pohl","year":"2019","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.molimm.2012.10.007","article-title":"Oxidation matters: The ubiquitin proteasome system connects innate immune mechanisms with MHC class I antigen presentation","volume":"55","author":"Warnatsch","year":"2013","journal-title":"Mol. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000367694","article-title":"Failure of Ubiquitin Proteasome System: Risk for Neurodegenerative Diseases","volume":"14","author":"Zheng","year":"2014","journal-title":"Neurodegener. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"\u00c7etin, G., Klafack, S., Studencka-Turski, M., Kr\u00fcger, E., and Ebstein, F. (2021). The Ubiquitin\u2013Proteasome System in Immune Cells. Biomolecules, 11.","DOI":"10.3390\/biom11010060"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00281-015-0486-4","article-title":"Dysfunction in protein clearance by the proteasome: Impact on autoinflammatory diseases","volume":"37","author":"Brehm","year":"2015","journal-title":"Semin. Immunopathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1096\/fasebj.11.14.9409544","article-title":"Pathways of ubiquitin conjugation","volume":"11","author":"Haas","year":"1997","journal-title":"FASEB J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bbamcr.2004.09.019","article-title":"Ubiquitin: Structures, functions, mechanisms","volume":"1695","author":"Pickart","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev.biochem.70.1.503","article-title":"Mechanisms Underlying Ubiquitination","volume":"70","author":"Pickart","year":"2001","journal-title":"Annu. Rev. Biochem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0092-8674(03)01074-2","article-title":"Back to the Future with Ubiquitin","volume":"116","author":"Pickart","year":"2004","journal-title":"Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nsmb.2780","article-title":"New insights into ubiquitin E3 ligase mechanism","volume":"21","author":"Berndsen","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.bbrc.2010.08.122","article-title":"Non-canonical ubiquitylation of the proneural protein Ngn2 occurs in both Xenopus embryos and mammalian cells","volume":"400","author":"McDowell","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1126\/science.1110340","article-title":"Ubiquitination on Nonlysine Residues by a Viral E3 Ubiquitin Ligase","volume":"309","author":"Cadwell","year":"2005","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"15458","DOI":"10.1074\/jbc.M809366200","article-title":"Ubiquitylation on Canonical and Non-canonical Sites Targets the Transcription Factor Neurogenin for Ubiquitin-mediated Proteolysis","volume":"284","author":"Vosper","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/cr.2012.58","article-title":"K48-linked ubiquitination and protein degradation regulate 53BP1 recruitment at DNA damage sites","volume":"22","author":"Mallette","year":"2012","journal-title":"Cell Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.cbpa.2004.09.009","article-title":"Polyubiquitin chains: Polymeric protein signals","volume":"8","author":"Pickart","year":"2004","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1242\/jcs.183954","article-title":"Ubiquitin chain diversity at a glance","volume":"129","author":"Akutsu","year":"2016","journal-title":"J. Cell Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1007\/s00018-016-2255-5","article-title":"The recognition of ubiquitinated proteins by the proteasome","volume":"73","author":"Grice","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ceb.2004.02.005","article-title":"The novel functions of ubiquitination in signaling","volume":"16","author":"Sun","year":"2004","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1074\/jbc.TM117.000117","article-title":"Ubiquitin signaling and autophagy","volume":"293","author":"Grumati","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.bbamcr.2013.06.027","article-title":"Regulation of proteolysis by human deubiquitinating enzymes","volume":"1843","author":"Eletr","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.cell.2005.11.007","article-title":"A Genomic and Functional Inventory of Deubiquitinating Enzymes","volume":"123","author":"Nijman","year":"2005","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1042\/bse0410031","article-title":"Proteasomes","volume":"41","author":"Dahlmann","year":"2005","journal-title":"Essays Biochem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1515\/hsz-2011-0285","article-title":"The proteasome: Molecular machinery and pathophysiological roles","volume":"393","author":"Tanaka","year":"2012","journal-title":"Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1146\/annurev-biochem-062917-011931","article-title":"Structure and Function of the 26S Proteasome","volume":"87","author":"Bard","year":"2018","journal-title":"Annu. Rev. Biochem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1016\/j.jmb.2017.05.027","article-title":"Proteasome Structure and Assembly","volume":"429","author":"Budenholzer","year":"2017","journal-title":"J. Mol. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/abbi.2000.2036","article-title":"Catalytic Activities of the 20 S Proteasome, a Multicatalytic Proteinase Complex","volume":"383","author":"Orlowski","year":"2000","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"14831","DOI":"10.1074\/jbc.275.20.14831","article-title":"Why Does Threonine, and Not Serine, Function as the Active Site Nucleophile in Proteasomes?","volume":"275","author":"Kisselev","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41580-018-0040-z","article-title":"Regulation of proteasome assembly and activity in health and disease","volume":"19","author":"Rousseau","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.tcb.2010.03.007","article-title":"Assembly, structure, and function of the 26S proteasome","volume":"20","author":"Bedford","year":"2010","journal-title":"Trends Cell Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.tibs.2012.11.009","article-title":"Functions of the 19S complex in proteasomal degradation","volume":"38","author":"Liu","year":"2013","journal-title":"Trends Biochem. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"29660","DOI":"10.1074\/jbc.270.50.29660","article-title":"Inhibition of Ubiquitin-mediated Proteolysis by the Arabidopsis 26 S Protease Subunit S5a","volume":"270","author":"Deveraux","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_34","first-page":"481","article-title":"Proteasome subunit Rpn13 is a novel ubiquitin receptor","volume":"453","author":"Husnjak","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.molcel.2007.06.033","article-title":"Docking of the Proteasomal ATPases\u2019 Carboxyl Termini in the 20S Proteasome\u2019s \u03b1 Ring Opens the Gate for Substrate Entry","volume":"27","author":"Smith","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.biochem.78.081507.101607","article-title":"Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome","volume":"78","author":"Finley","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Shin, J.Y., Muniyappan, S., Tran, N.-N., Park, H., Lee, S.B., and Lee, B.-H. (2020). Deubiquitination Reactions on the Proteasome for Proteasome Versatility. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155312"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.abb.2015.12.012","article-title":"Mammalian proteasome subtypes: Their diversity in structure and function","volume":"591","author":"Dahlmann","year":"2016","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.bbamcr.2004.10.004","article-title":"The proteasome and MHC class I antigen processing","volume":"1695","author":"Kloetzel","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.bbagen.2014.05.022","article-title":"ABC transporters in adaptive immunity","volume":"1850","author":"Seyffer","year":"2015","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1006\/scel.1993.1007","article-title":"The transporters associated with antigen presentation","volume":"4","author":"Townsend","year":"1993","journal-title":"Semin. Cell Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/jlb.56.5.571","article-title":"Role of proteasomes modified by interferon-\u03b3 in antigen processing","volume":"56","author":"Tanaka","year":"1994","journal-title":"J. Leukoc. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1007\/s00018-012-0938-0","article-title":"Emerging roles of immunoproteasomes beyond MHC class I antigen processing","volume":"69","author":"Ebstein","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.0105-2896.2005.00308.x","article-title":"Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing","volume":"207","author":"Strehl","year":"2005","journal-title":"Immunol. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/oxfordjournals.jbchem.a124327","article-title":"Interferon-Gamma Induces Different Subunit Organizations and Functional Diversity of Proteasomes","volume":"115","author":"Aki","year":"1994","journal-title":"J. Biochem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2010.07.036","article-title":"Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress","volume":"142","author":"Seifert","year":"2010","journal-title":"Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.molcel.2016.01.013","article-title":"mTORC1 Coordinates Protein Synthesis and Immunoproteasome Formation via PRAS40 to Prevent Accumulation of Protein Stress","volume":"61","author":"Yun","year":"2016","journal-title":"Mol. Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1756-8722-7-7","article-title":"Interferon-\u03b3-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines","volume":"7","author":"Niewerth","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Opitz, E., Koch, A., Klingel, K., Schmidt, F., Prokop, S., Rahnefeld, A., Sauter, M., Heppner, F.L., V\u00f6lker, U., and Kandolf, R. (2011). Impairment of Immunoproteasome Function by \u03b25i\/LMP7 Subunit Deficiency Results in Severe Enterovirus Myocarditis. PLoS Pathog., 7.","DOI":"10.1371\/journal.ppat.1002233"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.coi.2012.01.005","article-title":"Immunoproteasomes at the interface of innate and adaptive immune responses: Two faces of one enzyme","volume":"24","author":"Kloetzel","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1002\/eji.201444902","article-title":"Proteasome isoforms exhibit only quantitative differences in cleavage and epitope generation","volume":"44","author":"Mishto","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.1141915","article-title":"Regulation of CD8+ T Cell Development by Thymus-Specific Proteasomes","volume":"316","author":"Murata","year":"2007","journal-title":"Science"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41590-018-0186-z","article-title":"The immunoproteasome and thymoproteasome: Functions, evolution and human disease","volume":"19","author":"Murata","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.tibs.2013.10.004","article-title":"The unique functions of tissue-specific proteasomes","volume":"39","author":"Kniepert","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nrm3836","article-title":"Linear ubiquitin chains: NF-\u03baB signalling, cell death and beyond","volume":"15","author":"Iwai","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"10599","DOI":"10.1073\/pnas.92.23.10599","article-title":"Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway","volume":"92","author":"Alkalay","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/cr.2016.113","article-title":"OTULIN deficiency causes auto-inflammatory syndrome","volume":"26","author":"Fiil","year":"2016","journal-title":"Cell Res."},{"key":"ref_58","first-page":"694","article-title":"De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-\u03baB signalling","volume":"430","author":"Wertz","year":"2004","journal-title":"Nat. Cell Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"200","DOI":"10.15252\/emmm.201708089","article-title":"The immunoproteasome-specific inhibitor ONX 0914 reverses susceptibility to acute viral myocarditis","volume":"10","author":"Althof","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1161\/CIRCULATIONAHA.119.043171","article-title":"Heart-Specific Immune Responses in an Animal Model of Autoimmune-Related Myocarditis Mitigated by an Immunoproteasome Inhibitor and Genetic Ablation","volume":"141","author":"Bockstahler","year":"2020","journal-title":"Circulation"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.3389\/fimmu.2018.02386","article-title":"Immunoproteasome Inhibition Impairs T and B Cell Activation by Restraining ERK Signaling and Proteostasis","volume":"9","author":"Schmidt","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.4049\/jimmunol.1201183","article-title":"Immunoproteasome Subunit LMP7 Deficiency and Inhibition Suppresses Th1 and Th17 but Enhances Regulatory T Cell Differentiation","volume":"189","author":"Kalim","year":"2012","journal-title":"J. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00395-021-00848-w","article-title":"Mitigated viral myocarditis in A\/J mice by the immunoproteasome inhibitor ONX 0914 depends on inhibition of systemic inflammatory responses in CoxsackievirusB3 infection","volume":"116","author":"Goetzke","year":"2021","journal-title":"Basic Res. Cardiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.kint.2018.10.022","article-title":"Immunoproteasome inhibition induces plasma cell apoptosis and preserves kidney allografts by activating the unfolded protein response and suppressing plasma cell survival factors","volume":"95","author":"Li","year":"2019","journal-title":"Kidney Int."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.3389\/fimmu.2019.02756","article-title":"Contribution of the Unfolded Protein Response (UPR) to the Pathogenesis of Proteasome-Associated Autoinflammatory Syndromes (PRAAS)","volume":"10","author":"Ebstein","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ajhg.2010.10.031","article-title":"PSMB8 Encoding the \u03b25i Proteasome Subunit Is Mutated in Joint Contractures, Muscle Atrophy, Microcytic Anemia, and Panniculitis-Induced Lipodystrophy Syndrome","volume":"87","author":"Agarwal","year":"2010","journal-title":"Am. J. Hum. Genet."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"14914","DOI":"10.1073\/pnas.1106015108","article-title":"Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome","volume":"108","author":"Arima","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1172\/JCI58414","article-title":"A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans","volume":"121","author":"Kitamura","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.33368","article-title":"Mutations in proteasome subunit \u03b2 type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity","volume":"64","author":"Liu","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/ijd.12695","article-title":"Proteasome-associated autoinflammatory syndromes: Advances in pathogeneses, clinical presentations, diagnosis, and management","volume":"54","author":"McDermott","year":"2014","journal-title":"Int. J. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.jaad.2013.01.015","article-title":"A case of proteasome-associated auto-inflammatory syndrome with compound heterozygous mutations","volume":"69","author":"McDermott","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jaad.2009.04.046","article-title":"Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome","volume":"62","author":"Torrelo","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00393-017-0264-x","article-title":"Klinik und Genetik bei Proteasomen-assoziierten autoinflammatorischen Syndromen (PRAAS) Clinical aspects and genetics of proteasome-associated autoinflammatory syndromes (PRAAS)","volume":"76","author":"Feist","year":"2017","journal-title":"Z. Rheumatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1172\/JCI81260","article-title":"Additive loss-of-function proteasome subunit mutations in CANDLE\/PRAAS patients promote type I IFN production","volume":"125","author":"Brehm","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2249.2011.04533.x","article-title":"Immunology in clinic review series; focus on autoinflammatory diseases: Update on monogenic autoinflammatory diseases: The role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1","volume":"167","year":"2012","journal-title":"Clin. Exp. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10875-016-0359-1","article-title":"Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease","volume":"37","author":"Rice","year":"2017","journal-title":"J. Clin. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1089\/jir.2017.0127","article-title":"Development of a Validated Interferon Score Using NanoString Technology","volume":"38","author":"Kim","year":"2018","journal-title":"J. Interf. Cytokine Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/pai.13400","article-title":"SIGLEC1 (CD169) as a potential diagnostical screening marker for monogenic interferonopathies","volume":"32","author":"Orak","year":"2021","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ajhg.2018.04.010","article-title":"Heterozygous Truncating Variants in POMP Escape Nonsense-Mediated Decay and Cause a Unique Immune Dysregulatory Syndrome","volume":"102","author":"Poli","year":"2018","journal-title":"Am. J. Hum. Genet."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.jaci.2018.12.1012","article-title":"Novel proteasome assembly chaperone mutations in PSMG2\/PAC2 cause the autoinflammatory interferonopathy CANDLE\/PRAAS4","volume":"143","author":"Brehm","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jaci.2019.11.024","article-title":"PSMB10, the last immunoproteasome gene missing for PRAAS","volume":"145","author":"Sarrabay","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/hmg\/ddaa032","article-title":"Biallelic variants in PSMB1 encoding the proteasome subunit \u03b26 cause impairment of proteasome function, microcephaly, intellectual disability, developmental delay and short stature","volume":"29","author":"Ansar","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ajhg.2017.01.003","article-title":"De Novo Disruption of the Proteasome Regulatory Subunit PSMD12 Causes a Syndromic Neurodevelopmental Disorder","volume":"100","author":"Besnard","year":"2017","journal-title":"Am. J. Hum. Genet."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"11861","DOI":"10.15252\/emmm.201911861","article-title":"Proteasome subunit PSMC3 variants cause neurosensory syndrome combining deafness and cataract due to proteotoxic stress","volume":"12","author":"Ebstein","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e432","DOI":"10.1038\/bcj.2016.40","article-title":"Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response","volume":"6","author":"Nikesitch","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41580-020-0250-z","article-title":"Mechanisms, regulation and functions of the unfolded protein response","volume":"21","author":"Hetz","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/ni.2991","article-title":"Emerging functions of the unfolded protein response in immunity","volume":"15","author":"Janssens","year":"2014","journal-title":"Nat. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.3389\/fimmu.2019.02900","article-title":"Molecular Insight into the IRE1\u03b1-Mediated Type I Interferon Response Induced by Proteasome Impairment in Myeloid Cells of the Brain","volume":"10","author":"Junker","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1007\/s00726-016-2318-9","article-title":"GCN2- and eIF2\u03b1-phosphorylation-independent, but ATF4-dependent, induction of CARE-containing genes in methionine-deficient cells","volume":"48","author":"Mazor","year":"2016","journal-title":"Amino Acids"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1101\/gad.269324.115","article-title":"GCN2 sustains mTORC1 suppression upon amino acid deprivation by inducing Sestrin2","volume":"29","author":"Ye","year":"2015","journal-title":"Genes Dev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/sj.emboj.7600596","article-title":"TRB3, a novel ER stress-inducible gene, is induced via ATF4\u2013CHOP pathway and is involved in cell death","volume":"24","author":"Ohoka","year":"2005","journal-title":"EMBO J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.bbrc.2012.09.074","article-title":"Induction of REDD1 gene expression in the liver in response to endoplasmic reticulum stress is mediated through a PERK, eIF2\u03b1 phosphorylation, ATF4-dependent cascade","volume":"427","author":"Kimball","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/j.cell.2015.11.045","article-title":"Limiting Cholesterol Biosynthetic Flux Spontaneously Engages Type I IFN Signaling","volume":"163","author":"York","year":"2015","journal-title":"Cell"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Patel, P.N., Hunt, R., Pettigrew, Z.J., Shirley, J.B., Vogel, T.P., and de Guzman, M.M. (2021). Successful treatment of chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome with tofacitinib. Pediatr. Dermatol.","DOI":"10.1111\/pde.14517"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11926-018-0749-x","article-title":"An Update on Autoinflammatory Diseases: Relopathies","volume":"20","author":"Steiner","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s00393-020-00794-3","article-title":"Klassifikation autoinflammatorischer Erkrankungen anhand pathophysiologischer Mechanismen","volume":"79","author":"Kallinich","year":"2020","journal-title":"Z. Rheumatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/ni.2457","article-title":"Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency","volume":"13","author":"Boisson","year":"2012","journal-title":"Nat. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1084\/jem.20141130","article-title":"Human HOIP and LUBAC deficiency underlies autoinflammation, immunodeficiency, amylopectinosis, and lymphangiectasia","volume":"212","author":"Boisson","year":"2015","journal-title":"J. Exp. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"10127","DOI":"10.1073\/pnas.1612594113","article-title":"Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease","volume":"113","author":"Zhou","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/ng.3459","article-title":"Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease","volume":"48","author":"Zhou","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.jaci.2016.09.038","article-title":"Haploinsufficiency of TNFAIP3 (A20) by germline mutation is involved in autoimmune lymphoproliferative syndrome","volume":"139","author":"Takagi","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1084\/jem.20151529","article-title":"Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome","volume":"213","author":"Meuwissen","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Basters, A., Knobeloch, K.-P., and Fritz, G. (2018). USP18\u2014A multifunctional component in the interferon response. Biosci. Rep., 38.","DOI":"10.1042\/BSR20180250"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Gruber, C., Martin-Fernandez, M., Ailal, F., Qiu, X., Taft, J., Altman, J., Rosain, J., Buta, S., Bousfiha, A., and Casanova, J.-L. (2020). Homozygous STAT2 gain-of-function mutation by loss of USP18 activity in a patient with type I interferonopathy. J. Exp. Med., 217.","DOI":"10.1084\/jem.20192319"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1056\/NEJMoa1905633","article-title":"JAK Inhibitor Therapy in a Child with Inherited USP18 Deficiency","volume":"382","author":"Alsohime","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease","volume":"383","author":"Beck","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Poulter, J., Collins, J.C., Cargo, C., de Tute, R.M., Evans, P., Cardona, D.O., Bowen, D.T., Cunnington, J.R., Baguley, E., and Quinn, M. (2021). Novel somatic mutations in UBA1 as a cause of VEXAS syndrome. Blood.","DOI":"10.1182\/blood.2020010286"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/art.21782","article-title":"Tissue-specific up-regulation of the proteasome subunit \u03b25i (LMP7) in Sj\u00f6gren\u2019s syndrome","volume":"54","author":"Egerer","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1136\/ard.2005.045930","article-title":"Immunoproteasome subunit LMP2 expression is deregulated in Sjogren\u2019s syndrome but not in other autoimmune disorders","volume":"65","author":"Krause","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1084\/jem.184.4.1313","article-title":"Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus","volume":"184","author":"Feist","year":"1996","journal-title":"J. Exp. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/1529-0131(199904)42:4<697::AID-ANR12>3.0.CO;2-H","article-title":"Autoantibodies in primary Sj\u00f6gren\u2019s syndrome are directed against proteasomal subunits of the alpha and beta type","volume":"42","author":"Feist","year":"1999","journal-title":"Arthritis Rheum."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1093\/brain\/awf274","article-title":"The proteasome is a major autoantigen in multiple sclerosis","volume":"125","author":"Mayo","year":"2002","journal-title":"Brain"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/art.21970","article-title":"Anti-20S proteasome autoantibodies inhibit proteasome stimulation by proteasome activator PA28","volume":"54","author":"Brychcy","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_118","first-page":"2045","article-title":"Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases","volume":"29","author":"Egerer","year":"2002","journal-title":"J. Rheumatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41927-020-00137-4","article-title":"Serum 20S proteasome levels are associated with disease activity in MPO-ANCA-associated microscopic polyangiitis","volume":"4","author":"Maruyama","year":"2020","journal-title":"BMC Rheumatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nm.1978","article-title":"A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis","volume":"15","author":"Muchamuel","year":"2009","journal-title":"Nat. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"634","DOI":"10.4049\/jimmunol.0903182","article-title":"Prevention of Experimental Colitis by a Selective Inhibitor of the Immunoproteasome","volume":"185","author":"Basler","year":"2010","journal-title":"J. Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/gut.2009.203554","article-title":"Targeting the proteasome: Partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis","volume":"59","author":"Schmidt","year":"2010","journal-title":"Gut"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/eji.201545578","article-title":"Inhibition and deficiency of the immunoproteasome subunit LMP7 attenuates LCMV-induced meningitis","volume":"46","author":"Mundt","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.4049\/jimmunol.1900182","article-title":"Immunoproteasome Inhibition Selectively Kills Human CD14+ Monocytes and as a Result Dampens IL-23 Secretion","volume":"203","author":"Basler","year":"2019","journal-title":"J. Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/emmm.201303543","article-title":"Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis","volume":"6","author":"Basler","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.clim.2016.07.018","article-title":"The proteasome\u2014Victim or culprit in autoimmunity","volume":"172","author":"Feist","year":"2016","journal-title":"Clin. Immunol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis","volume":"14","author":"Neubert","year":"2008","journal-title":"Nat. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The Pathogenesis of Rheumatoid Arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"102741","DOI":"10.1016\/j.autrev.2020.102741","article-title":"An Overview of the NF-kB mechanism of pathophysiology in rheumatoid arthritis, investigation of the NF-kB ligand RANKL and related nutritional interventions","volume":"20","author":"Ilchovska","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_130","first-page":"92","article-title":"The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients","volume":"27","author":"Oerlemans","year":"2009","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1046\/j.1365-2249.2001.01677.x","article-title":"Regulation of rheumatoid synoviocyte proliferation by endogenous p53 induction","volume":"126","author":"Migita","year":"2001","journal-title":"Clin. Exp. Immunol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/S0140-6736(19)30546-X","article-title":"Novel paradigms in systemic lupus erythematosus","volume":"393","author":"Furie","year":"2019","journal-title":"Lancet"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/art.33333","article-title":"Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells","volume":"64","author":"Ichikawa","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1136\/annrheumdis-2012-201586","article-title":"IFN\u03b1 and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus","volume":"72","author":"Rose","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"102282","DOI":"10.1016\/j.jaut.2019.05.010","article-title":"The proteasome activator REG\u03b3 counteracts immunoproteasome expression and autoimmunity","volume":"103","author":"Yao","year":"2019","journal-title":"J. Autoimmun."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2474-15-414","article-title":"Increased proteasome activator 28 gamma (PA28\u03b3) levels are unspecific but correlate with disease activity in rheumatoid arthritis","volume":"15","author":"Gruner","year":"2014","journal-title":"BMC Musculoskelet. Disord."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00393-019-0625-8","article-title":"Sj\u00f6gren-Syndrom","volume":"78","author":"Witte","year":"2019","journal-title":"Z. Rheumatol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000024427","article-title":"Diagnostic importance of anti-proteasome antibodies","volume":"123","author":"Feist","year":"2000","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.3899\/jrheum.081098","article-title":"Expression of Proteasomal Immunosubunit \u00df1i Is Dysregulated in Inflammatory Infiltrates of Minor Salivary Glands in Sj\u00f6gren\u2019s Syndrome","volume":"36","author":"Morawietz","year":"2009","journal-title":"J. Rheumatol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3899\/jrheum.120680","article-title":"Gene Expression of Catalytic Proteasome Subunits and Resistance Toward Proteasome Inhibition of B Lymphocytes from Patients with Primary Sj\u00f6gren Syndrome","volume":"40","author":"Lesemann","year":"2013","journal-title":"J. Rheumatol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/cmi.2017.8","article-title":"Proteasome inhibition suppresses Th17 cell generation and ameliorates autoimmune development in experimental Sj\u00f6gren\u2019s syndrome","volume":"14","author":"Xiaohui","year":"2017","journal-title":"Cell. Mol. Immunol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"eaan5165","DOI":"10.1126\/sciimmunol.aan5165","article-title":"Human thymoproteasome variations influence CD8 T cell selection","volume":"2","author":"Nitta","year":"2017","journal-title":"Sci. Immunol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/gut.42.4.477","article-title":"Activation of nuclear factor kappa B in inflammatory bowel disease","volume":"42","author":"Schreiber","year":"1998","journal-title":"Gut"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00384-009-0679-1","article-title":"Expression of catalytic proteasome subunits in the gut of patients with Crohn\u2019s disease","volume":"24","author":"Visekruna","year":"2009","journal-title":"Int. J. Color. Dis."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/ibd.20805","article-title":"Comparative expression analysis and characterization of 20S proteasomes in human intestinal tissues","volume":"15","author":"Visekruna","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1172\/JCI28804","article-title":"Proteasome-mediated degradation of I\u03baB\u03b1 and processing of p105 in Crohn disease and ulcerative colitis","volume":"116","author":"Visekruna","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"113964","DOI":"10.1016\/j.bcp.2020.113964","article-title":"Immunoproteasome inhibitor DPLG3 attenuates experimental colitis by restraining NF-\u03baB activation","volume":"177","author":"Moallemian","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"50447","DOI":"10.18632\/oncotarget.14579","article-title":"Prevention of colitis-associated cancer by selective targeting of immunoproteasome subunit LMP7","volume":"8","author":"Vachharajani","year":"2017","journal-title":"Oncotarget"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Basler, M., Lindstrom, M.M., LaStant, J.J., Bradshaw, J.M., Owens, T.D., Schmidt, C., Maurits, E., Tsu, C., Overkleeft, H.S., and Kirk, C.J. (2018). Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity. EMBO Rep., 19.","DOI":"10.15252\/embr.201846512"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Mishto, M., Bellavista, E., Ligorio, C., Textoris-Taube, K., Santoro, A., Giordano, M., D\u2019Alfonso, S., List\u00ec, F., Nacmias, B., and Cellini, E. (2010). Immunoproteasome LMP2 60HH Variant Alters MBP Epitope Generation and Reduces the Risk to Develop Multiple Sclerosis in Italian Female Population. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0009287"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1006\/jaut.2000.0370","article-title":"Treatment of Established Relapsing Experimental Autoimmune Encephalomyelitis with the Proteasome Inhibitor PS-5191","volume":"14","author":"VanderLugt","year":"2000","journal-title":"J. Autoimmun."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0165-5728(01)00352-6","article-title":"Protection against experimental autoimmune encephalomyelitis by a proteasome modulator","volume":"118","author":"Hosseini","year":"2001","journal-title":"J. Neuroimmunol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s13671-013-0066-6","article-title":"Genetic Epidemiology of Psoriasis","volume":"3","author":"Gupta","year":"2014","journal-title":"Curr. Dermatol. Rep."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jdermsci.2017.12.002","article-title":"Ubiquitination-proteasome system: A new player in the pathogenesis of psoriasis and clinical implications","volume":"89","author":"Yang","year":"2018","journal-title":"J. Dermatol. Sci."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_157","first-page":"678","article-title":"Identification of possible pathogenic pathways in Beh\u00e7et\u2019s disease using genome-wide association study data from two different populations","volume":"23","author":"Remmers","year":"2014","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrd1959","article-title":"Success in translational research: Lessons from the development of bortezomib","volume":"5","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1080\/14397595.2018.1432331","article-title":"Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus","volume":"28","author":"Ishii","year":"2018","journal-title":"Mod. Rheumatol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1093\/rheumatology\/kez623","article-title":"A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE","volume":"59","author":"Osmani","year":"2020","journal-title":"Rheumatology"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrneph.2016.20","article-title":"Plasma cells as an innovative target in autoimmune disease with renal manifestations","volume":"12","author":"Hiepe","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"13700","DOI":"10.1111\/petr.13700","article-title":"Bortezomib for autoimmune hemolytic anemia after intestinal transplantation","volume":"24","author":"Knops","year":"2020","journal-title":"Pediatr. Transplant."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"28725","DOI":"10.1002\/pbc.28725","article-title":"Bortezomib treatment of steroid-refractory Evans syndrome in children","volume":"67","author":"Beydoun","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1111\/trf.12614","article-title":"Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: A case report","volume":"54","author":"Yates","year":"2014","journal-title":"Transfusion"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/RHU.0000000000000210","article-title":"Refractory Primary Sj\u00f6gren Syndrome Successfully Treated with Bortezomib","volume":"21","author":"Llorente","year":"2015","journal-title":"J. Clin. Rheumatol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2567.2007.02761.x","article-title":"Proteasome inhibition suppresses essential immune functions of human CD4+T cells","volume":"124","author":"Berges","year":"2008","journal-title":"Immunology"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e00482","DOI":"10.1002\/prp2.482","article-title":"Inhibiting the immunoproteasome\u2019s \u03b25i catalytic activity affects human peripheral blood-derived immune cell viability","volume":"7","author":"Pletinckx","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/WNL.0000000000003536","article-title":"Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis","volume":"88","author":"Scheibe","year":"2016","journal-title":"Neurology"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-020-04516-7","article-title":"Generate-Boost: Study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis","volume":"21","author":"Wickel","year":"2020","journal-title":"Trials"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/toxics3030294","article-title":"An Overview of Bortezomib-Induced Neurotoxicity","volume":"3","author":"Meregalli","year":"2015","journal-title":"Toxics"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"11127","DOI":"10.1021\/acs.jmedchem.8b01201","article-title":"Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2S,3R)-N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenamide)","volume":"61","author":"Johnson","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1556\/1886.2017.00025","article-title":"Low neurotoxicity of ONX-0914 supports the idea of specific immunoproteasome inhibition as a side-effect-limiting, therapeutic strategy","volume":"7","author":"Landgraf","year":"2017","journal-title":"Eur. J. Microbiol. Immunol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/pr.117.015370","article-title":"A Practical Review of Proteasome Pharmacology","volume":"71","author":"Thibaudeau","year":"2019","journal-title":"Pharmacol. Rev."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bbmt.2015.06.010","article-title":"Inhibition of the Immunoproteasome Subunit LMP7 with ONX 0914 Ameliorates Graft-versus-Host Disease in an MHC-Matched Minor Histocompatibility Antigen\u2013Disparate Murine Model","volume":"21","author":"Zilberberg","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1096\/fj.201601147R","article-title":"PR-957, a selective inhibitor of immunoproteasome subunit low-MW polypeptide 7, attenuates experimental autoimmune neuritis by suppressing T h 17-cell differentiation and regulating cytokine production","volume":"31","author":"Liu","year":"2016","journal-title":"FASEB J."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41435-020-00109-1","article-title":"Recent insights how combined inhibition of immuno\/proteasome subunits enables therapeutic efficacy","volume":"21","author":"Basler","year":"2020","journal-title":"Genes Immun."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"7032","DOI":"10.1021\/acs.jmedchem.9b00509","article-title":"Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability","volume":"62","author":"Ladi","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.chembiol.2017.05.010","article-title":"Proteasome Activation by Small Molecules","volume":"24","author":"Leestemaker","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nm.4011","article-title":"Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling","volume":"22","author":"Myeku","year":"2016","journal-title":"Nat. Med."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/jnc.12647","article-title":"Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington\u2019s disease","volume":"129","author":"Liu","year":"2014","journal-title":"J. Neurochem."},{"key":"ref_184","first-page":"179","article-title":"Enhancement of proteasome activity by a small-molecule inhibitor of USP14","volume":"467","author":"Lee","year":"2010","journal-title":"Nat. Cell Biol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/8\/1783\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:50:00Z","timestamp":1760161800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/8\/1783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":184,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["jcm10081783"],"URL":"https:\/\/doi.org\/10.3390\/jcm10081783","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]}}}